Myocardial ischemia/reperfusion (I/R) injury is associated with contractile dysfunction, arrhythmias, and myocyte death. Intracellular Ca²⁺ overload with reduced activity of sarco(endo)plasmic reticulum Ca²⁺ATPase (SERCA) is a critical mechanism of this injury. While upregulation of SERCA function is well documented to improve postischemic cardiac function, there are conflicting reports where pharmacological inhibition of SERCA improved postischemic function. SERCA2a is the primary cardiac isoform regulating intracellular Ca²⁺ homeostasis, however, SERCA1a has been shown to substitute SERCA2a with faster Ca²⁺ transport kinetics. Therefore, to further address this issue and to evaluate whether SERCA1a expression could improve postischemic cardiac function and myocardial salvage, in vitro and in vivo myocardial I/R studies were performed on SERCA1a transgenic (SERCA1a^+/+) and non-transgenic (NTG) mice. Langendorff-perfused hearts were subjected to 30 min of global ischemia followed by reperfusion. Baseline preischemic coronary flow and LV developed pressure (LVDP) were significantly greater in SERCA1a^+/+ mice compared with NTG mice. Independent of reperfusion-induced oxidative stress, SERCA1a^+/+ hearts demonstrated greatly improved postischemic (45 min) contractile recovery with less persistent arrhythmias compared to NTG hearts. Morphometry showed better-preserved myocardial structure with less infarction, and electron microscopy demonstrated better-preserved myofibrillar and mitochondrial ultrastructure in SERCA1a^+/+ hearts. Importantly, intra-ischemic Ca²⁺ levels were significantly lower in SERCA1a^+/+ hearts. The cardioprotective effect of SERCA1a was also observed during in vivo regional I/R with reduced myocardial infarct size after 24 h reperfusion. Thus, SERCA1a^+/+ hearts were markedly protected against I/R injury, suggesting that increased expression of SERCA 1a isoform reduces postischemic Ca²⁺ overload and thus provides potent myocardial protection.